Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development

Report Summary

GBI Research, a leading business intelligence provider, has released its latest research “Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development”, which provides insights into the unmet needs targeted by late stage pipeline molecules across major therapy areas. The report examines the safety, efficacy parameters of molecules in development. The report includes insights into the R&D pipeline various therapy areas and identifies potential blockbusters.
In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by GBI Research’s team of experts.

Scope

• Profiles of promising late stage pipeline molecules across various therapy areas
• Analysis of safety, efficacy, mechanism of actions of major pipeline drugs targeted at major therapy areas
• Comparison of late stage drugs based on safety, efficacy, mechanism of action, unmet need targeted and stage of disease targeted

Reasons to buy

• Build effective strategies to launch their pipeline products by identifying geographies with high potential for growth.
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Introduction
2.1 GBI Research Report Guidance

3 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology
3.1 Comparative Analysis of Late Stage Pipeline Molecules in NSCLC
3.1.1 Overview
3.1.2 Opportunity and Unmet Need
3.1.3 Strategic Pipeline Assessment
3.1.4 Comparative Analysis of Late Stage Pipeline Molecules Based on Major Characteristics
3.1.5 Promising Drugs under Clinical Development
3.1.6 Other Promising Drugs under Clinical Development
3.2 Comparative Analysis of Late Stage Pipeline Molecules in Colorectal Cancer
3.2.1 Overview
3.2.2 Opportunity and Unmet Need
3.2.3 Strategic Pipeline Assessment
3.2.4 Trends in Colorectal Cancer Pipeline
3.2.5 Comparative Analysis Based on Major Characteristics
3.2.6 Promising Drugs Under Clinical Development
3.3 Comparative Analysis of Late Stage Pipeline Molecules in Breast Cancer
3.3.1 Overview
3.3.2 Opportunity and Unmet Need
3.3.3 Strategic Pipeline Assessment
3.3.4 Comparative Analysis Based on Major Characteristics
3.3.5 Promising Drugs under Clinical Development
3.4 Comparative Analysis of Late Stage Pipeline Molecules in Prostate Cancer
3.4.1 Overview
3.4.2 Opportunity and Unmet Need
3.4.3 Strategic Pipeline Assessment
3.4.4 Trends in Prostate Cancer Pipeline
3.4.5 Comparative Analysis Based on Major Characteristics
3.4.6 Promising Drugs under Clinical Development

4 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Metabolic Disorders
4.1 Comparative Analysis of Late Stage Pipeline Molecules in Type II Diabetes
4.1.1 Overview
4.1.2 Opportunity and Unmet Need
4.1.3 Strategic Pipeline Assessment
4.1.4 Comparative Analysis Based on Major Characteristics
4.1.5 Promising Drugs under Clinical Development

5 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Respiratory Diseases
5.1 Comparative Analysis of Late Stage Pipeline Molecules in COPD
5.1.1 Overview
5.1.2 Opportunity and Unmet Need
5.1.3 Strategic Pipeline Assessment
5.1.4 Comparative Analysis Based on Major Characteristics
5.1.5 Promising Drugs under Clinical Development

6 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Musculoskeletal
6.1 Comparative Analysis of Late Stage Pipeline Molecules in Rheumatoid Arthritis
6.1.1 Overview
6.1.2 Opportunity and Unmet Need
6.1.3 Strategic Pipeline Assessment
6.1.4 Comparative Analysis Based on Major Characteristics
6.1.5 Promising Drugs under Clinical Development

7 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Central Nervous System
7.1 Comparative Analysis of Late Stage Pipeline Molecules in Epilepsy
7.1.1 Overview
7.1.2 Opportunity and Unmet Need
7.1.3 Strategic Pipeline Assessment
7.1.4 Comparative Analysis Based on Major Characteristics
7.1.5 Promising Drugs under Clinical Development
7.2 Comparative Analysis of Late Stage Pipeline Molecules in Multiple Sclerosis
7.2.1 Overview
7.2.2 Opportunity and Unmet Need
7.2.3 Strategic Pipeline Assessment
7.2.4 Comparative Analysis Based on Major Characteristics
7.2.5 Promising Drugs under Clinical Development
7.3 Comparative Analysis of Late Stage Pipeline Molecules in Major Depressive Disorder
7.3.1 Overview
7.3.2 Opportunity and Unmet Need
7.3.3 Strategic Pipeline Assessment
7.3.4 Comparative Analysis Based on Major Characteristics
7.3.5 Promising Drugs under Clinical Development

8 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Immunology
8.1 Comparative Analysis of Late Stage Pipeline Molecules in Crohn’s Disease
8.1.1 Overview
8.1.2 Opportunity and Unmet Need
8.1.3 Strategic Pipeline Assessment
8.1.4 Comparative Analysis Based on Major Characteristics
8.1.5 Promising Drugs under Clinical Development

9 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Cardiovascular
9.1 Comparative Analysis of Late Stage Pipeline Molecules in Hypertension
9.1.1 Overview
9.1.2 Opportunity and Unmet Need
9.1.3 Strategic Pipeline Assessment
9.1.4 Comparative Analysis Based on Major Characteristics
9.1.5 Promising Drugs under Clinical Development

10 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Infectious Disease
10.1 Comparative Analysis of Late Stage Pipeline Molecules in HIV/ AIDS
10.1.1 Overview
10.1.2 Opportunity and Unmet Need
10.1.3 Strategic Pipeline Assessment
10.1.4 Comparative Analysis Based on Major Characteristics
10.1.5 Promising Drugs under Clinical Development

11 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Gastrointestinal Diseases
11.1 Comparative Analysis of Late Stage Pipeline Molecules in Ulcerative Colitis
11.1.1 Overview
11.1.2 Opportunity and Unmet Need
11.1.3 Strategic Pipeline Assessment
11.1.4 Comparative Analysis Based on Major Characteristics
11.1.5 Promising Drugs under Clinical Development

12 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Conclusion
12.1 Oncology Pipeline Holds Most Prominence for Market Players
12.2 Colorectal Cancer Most Noteworthy Indications With Respect To Phase III Activity
12.3 An Average Of 50% Unmet Need Common in Oncology Therapeutics Followed By RA
12.4 Kinase Inhibitors - Most Important First-In-class Drug
12.5 Receptor Tyrosine Kinase and Vaccines Are Major Promising Class Based On Sales Forecast for Oncology

13 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Appendix
13.1 Marketed Definitions
13.2 Abbreviations
13.3 Research Methodology
13.3.1 Coverage
13.3.2 Secondary Research
13.3.3 Primary Research
13.3.4 Expert Panel Validation
13.4 Contact Us
13.5 Disclaimer
13.6 Sources

List of Tables

Table 1: Comparative Analysis of Late Stage Pipeline Molecules in NSCLC, Based on Major Characteristics
Table 2: Comparative Analysis of Late Stage Pipeline Molecules in NSCLC, Other Promising Candidates in Late Stage Pipeline, 2011
Table 3: Comparative Analysis of Late Stage Pipeline Molecules in Colorectal Cancer, Based on Major Characteristics
Table 4: Comparative Analysis of Late Stage Pipeline Molecules in Breast Cancer, Based on Major Characteristics
Table 5: Comparative Analysis of Late Stage Pipeline Molecules in Prostate Cancer, Based on Major Characteristics
Table 6: Comparative Analysis of Late Stage Pipeline Molecules in Type 2 Diabetes, Based on Major Characteristics
Table 7: Comparative Analysis of Late Stage Pipeline Molecules in COPD, Based on Major Characteristics
Table 8: Comparative Analysis of Late Stage Pipeline Molecules in Rheumatoid Arthritis, Based on Major Characteristics
Table 9: Comparative Analysis of Late Stage Pipeline Molecules in Epilepsy, Based on Major Characteristics
Table 10: Comparative Analysis of Late Stage Pipeline Molecules in Multiple Sclerosis, Based on Major Characteristics
Table 11: Comparative Analysis of Late Stage Pipeline Molecules in Major Depressive Disorder, Based on Major Characteristics
Table 12: Comparative Analysis of Late Stage Pipeline Molecules in Crohn’s Disease, Based on Major Characteristics
Table 13: Comparative Analysis of Late Stage Pipeline Molecules in Hypertension, Based on Major Characteristics
Table 14: Comparative Analysis of Late Stage Pipeline Molecules in HIV/AIDS, Based on Major Characteristics
Table 15: Comparative Analysis of Late Stage Pipeline Molecules in Ulcerative Colitis, Based on Major Characteristics

List of Figures

Figure 1: NSCLC Pipeline, Global, Mechanism of Action, 2010
Figure 2: NSCLC Pipeline, Global, Technology Analytics Framework, 2010
Figure 3: Colorectal Cancer Pipeline, Global, Mechanism of Action, 2010
Figure 4: Colorectal Cancer Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 5: Breast Cancer Pipeline, Global, Mechanism of Action, 2010
Figure 6: Breast Cancer Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 7: Prostate Cancer Pipeline, Global, Mechanism of Action, 2010
Figure 8: Prostate Cancer Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 9: Type 2 Diabetes Pipeline, Global, Mechanism of Action, 2010
Figure 10: Type 2 Diabetes Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 11: COPD Pipeline, Global, Mechanism of Action, 2010
Figure 12: COPD Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 13: Rheumatoid Arthritis Pipeline, Global, Mechanism of Action, 2010
Figure 14: Rheumatoid Arthritis Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 15: Epilepsy Pipeline, Global, Mechanism of Action, 2010
Figure 16: Epilepsy Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 17: Multiple Sclerosis Pipeline, Global, Mechanism of Action, 2010
Figure 18: Multiple Sclerosis Pipeline, Global, Technology Trends Analytic Framework, 2009
Figure 19: Major Depressive Disorder Pipeline, Global, Mechanism of Action, 2010
Figure 20: Major Depressive Disorder Pipeline, Technology Trends Analytic Framework, 2011
Figure 21: Crohn’s Disease Pipeline, Global, Mechanism of Action, 2010
Figure 22: Crohn’s Disease Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 23: Anti-hypertension Pipeline, Global, Mechanism of Action, 2010
Figure 24: Anti Hypertension Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 25: HIV/AIDS Pipeline, Global, Mechanism of Action, 2010
Figure 26: HIV/ AIDS Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 27: Ulcerative Colitis Pipeline, Global, Mechanism of Action, 2010
Figure 28: Ulcerative Colitis Pipeline, Global, Technology Trends Analytic Framework, 2009
Figure 29: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications, by Therapy Area, 2011
Figure 30: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications, by Phase, 2011
Figure 31: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications, Unmet Needs in % and $m, 2009
Figure 32: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications, Technology Trends, 2011
Figure 33: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications, Sales Forecast of Some Key Late Stage Pipeline Drugs in Oncology, ($m), 2017